Article
A Spatial Multi-Omic Framework Identifies Gliomas Permissive to TIL Expansion
2025-04-25
Abstract excerpt
<title>Abstract</title> <p>Tumor-infiltrating lymphocyte (TIL) therapy, recently approved by the FDA for melanoma, is an emerging modality for cell-based immunotherapy. However, its application in immunologically “cold” tumors such as glioblastoma remains limited due to sparse T cell infiltration, antigenic heterogeneity, and a suppressive tumor microenvironment. To identify genomic and spatial determinants of TI...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- dd18d99c-badb-5f04-9564-9060347b1c4f
- DOI
- 10.21203/rs.3.rs-6314842/v1
